Mark your calendars for February 22nd! In partnership with the Pascua Yaqui Tribe in Tucson, AZ, our next Let's Taco 'Bout Cancer is on Colorectal Cancer! RSVP with Community Health Nursing at (520) 879-6119 or (520) 879-6151 #CancerFreeAZ
Yanhao is my first graduate student. Today he passed oral comprehensive exam. This is a big milestone for him! I am so proud for how much he has accomplished so far. Congrats, Yanhao!
He also won the “outstanding research award” recently. The future is bright for him
The @ASCO election is open and I am proud to support my friend and mentor, Wells Messersmith - a committed leader for this incredible organization. @CUCancerCenter@rachnatshroff
👏 👏 @ajscott40 for great job championing @NRGonc GI005 COBRA trial evaluating ctDNA as predictive marker for adj chemo in stage II colon cancer at @SWOG-we recognize power of liquid biopsy & need definitive prospective data for acting on results! Trial open across US & Canada
University of Arizona Cancer Center Community Outreach and Engagement and Office of Diversity, Equity and Inclusion is strongly represented at #AACR23 to take part in the discussion of Hispanic health disparities. #CancerResearch#UACCCOE
Dr. Sharad Khurana, a hematologist at Banner – University Medicine and a member of the UArizona Cancer Center, was interviewed by KGUN 9 for a story on the importance of bone marrow registration. You can read and watch the KGUN9 interview here: https://t.co/dmZXcsHEnX
In honor of Women's History Month, and women currently making history: We're not sure how UACC Associate Director of Clinical Investigations, Rachna Shroff, gets it all done, but we're honored to have her help lead our team. Read a feature about her here: https://t.co/HhKj5P8FKx
Very excited to see the @NRGonc GI005 study team at @ASCO#GI23 - this ph 2/3 trial evaluating #ctDNA as a biomarker for adj chemo benefit in pts w/ low risk stage 2a colon cancer continues to enroll well in US and Canada! @SWOG@eaonc@ALLIANCE_org
The @NateraGenetics GALAXY trial in @NatureMedicine:
Molecular residual disease (measured by tumor informed ctDNA) & efficacy of adjuvant chemotherapy in patients with #ColorectalCancer. At 4w post survey, ctDNA+ is associated with recurrence.
#OpenAccess
https://t.co/kvbHLVeYKA